SEC 13F Intelligence

Baupost Group LLC/Ma / CGEM

Baupost Group LLC/Ma’s Cullinan Therapeutics Inc Position

Does Baupost Group LLC/Ma own Cullinan Therapeutics Inc (CGEM)? Not currently — the last reported position was 429.6K shares worth $6M in Q3 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$6M
Q3 2022
Shares
429.6K
% of Portfolio
+0.10%
Quarters Held
7
position exited

Position History CGEM

Reported value by quarter
Q1 ’21: $72MQ1 ’21Q2 ’21: $46MQ2 ’21Q3 ’21: $40MQ3 ’21Q4 ’21: $23MQ4 ’21Q1 ’22: $16MQ1 ’22Q2 ’22: $20MQ2 ’22Q3 ’22: $6MQ3 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2022429.6K$6M+0.10%
Q2 20221.54M$20M+0.29%
Q1 20221.54M$16M+0.17%
Q4 20211.54M$23M+0.22%
Q3 20211.84M$40M+0.37%
Q2 20211.84M$46M+0.38%
Q1 20211.84M$72M+0.57%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Baupost Group LLC/Ma’s full portfolio or all institutional holders of CGEM.